Skip to main content

Advertisement

SpringerLink
Log in

CDP 571

Anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Dhainaut J-FA, Vincent J-L, Richard C. et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Critical Care Medicine 23: 1461–1469, Sep 1995

    Article  PubMed  CAS  Google Scholar 

  2. Celltech Group plc. Celltech Announces Results From CDP 571 Phase III Studies in Crohn’s Disease. Media Release: 30 Jul 2002. Available from: URL: http://www.celltechgroup.com

    Google Scholar 

  3. Hamauer S, Present D, Sandborn W. et al. CDP571, a novel humanized anti-TNF-alpha antibody: a well tolerated option for Crohn’s disease after previous hypersensitivity to infliximab. American J Gastroenterology 97 (Suppl.): 277, Sep 2002

    Article  Google Scholar 

  4. Ofei O, Hurel S, Newkirk J. et al. Effects of an engineered human TNF-alpha antibody (CDP571) on insulin sensitivity and glycaemic control in patients with non-insulin-dependent diabetes mellitus. Diabetic Medicine 12 (Suppl. 2): 15, 1995

    Google Scholar 

  5. Warren BF, Watkins PE, Foulkes R. Anti TNF alpha treatment of a model of human ulcerative colitis. Gut 35 (Suppl. 2): 50, 1994

    Google Scholar 

  6. Bloxham DP. Therapeutic applications of anti-TNF monoclonal antibodies. Expert opinion on Investigational Drugs 3: 907–912, Sep 1994

    Article  Google Scholar 

  7. Watkins PE, Foulkes R, Stephens S. The treatment of ulcerative colitis with anti-tumour necrosis factor alpha antibody. Falk Symposium Inflammatory Bowel Diseases: 178, 29 Jun 1995

    Google Scholar 

  8. Rankin ECC, Ravirajan CT, Ehrenstein MR. et al. Serological effects following treatment with an engineered human anti-TNF alpha antibody, CDP571, in patients with rheumatoid arthritis. British Journal of Rheumatology 34 (Suppl. 1): 101, 1995

    Google Scholar 

  9. Choy EHS, Kassimos D, Kingsley GH. et al. The effect of an engineered human anti-tumour necrosis factor alpha antibody on interleukin-6 and bone markers in rheumatoid arthritis patients. Arthritis and Rheumatism 38 (Suppl.): 185, Sep 1995

    Google Scholar 

  10. Stack WA, Mann SD, Roy AJ. et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 349: 521–524, 22 Feb 1997

    Article  PubMed  CAS  Google Scholar 

  11. Feagan BG, Sandborn WJ, Baker JP. et al. A randomized, double-blind, placebo-controlled, multicenter trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-depen-dent Crohn’s disease. Gut 45 (Suppl. V): 131, Nov 1999

    Google Scholar 

  12. Sandborn WJ, Targan SR, Wolf DC. et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for the induction and maintenance of clinical improvement in patients with moderate to severely active Crohn’s disease. Gut 45 (Suppl. V): 133, Nov 1999

    Google Scholar 

  13. Feagan BG, Sandborn WJ, Baker JP. et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-depen-dent Crohn’s disease. Gastroenterology 118 (Suppl. 2): 655, Part 1, Apr 2000

    Article  Google Scholar 

  14. Sandborn WJ, Feagan BG, Hanauer SB. et al. An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330–1338, May 2001

    Article  PubMed  CAS  Google Scholar 

  15. Rankin ECC, Choy EHS, Kassimos D. et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatology 34: 334–342, Apr 1995

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

CDP 571. Drugs R&D 4, 174–178 (2003). https://doi.org/10.2165/00126839-200304030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304030-00006

Keywords

Search

Navigation